![](https://webarchive.library.unt.edu/web/20090114235335im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/web/20090114235335im_/http://www.cancer.gov/images/spacer.gif)
PEG-interleukin-2 A complex of polyethylene glycol conjugated with human recombinant cytokine interleukin-2 (IL-2) with antineoplastic activity. PEG-interleukin-2 induces natural killer (NK) cell activity and the production of interferon-gamma (IFN-gamma), and enhances T cell-mediated cytotoxicity. Pegylation of IL-2 protects the cytokine from degradation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/web/20090114235335im_/http://www.cancer.gov/images/spacer.gif)
Synonym: | ![](https://webarchive.library.unt.edu/web/20090114235335im_/http://www.cancer.gov/images/spacer.gif) | polyethylene glycol-modified recombinant interleukin-2 | | ![](https://webarchive.library.unt.edu/web/20090114235335im_/http://www.cancer.gov/images/spacer.gif) | Abbreviation: | ![](https://webarchive.library.unt.edu/web/20090114235335im_/http://www.cancer.gov/images/spacer.gif) | PEG-IL-2 | | ![](https://webarchive.library.unt.edu/web/20090114235335im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20090114235335im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20090114235335im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/web/20090114235335im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20090114235335im_/http://www.cancer.gov/images/spacer.gif) |